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Summary
The World Health Organization’s new classification of breast tumors has just been pub-
lished. This review aims to examine the morphological categorization of breast carcino-
mas which is still principally based on histological features and follows the traditions of 
histological typing. It gives a subjective and critical view on the WHO classifications and 
their changes over time, and describes the changes related to some of the most common 
or challenging breast carcinomas: in situ carcinomas, invasive breast carcinomas of no 
special type, lobular, cribriform, tubular, mucinous, papillary, metaplastic carcinomas and 
carcinomas with medullary pattern and those with apocrine differentiation are discussed in 
more details. Although the 5th edition of the classification is not perfect, it has advantages 
which are mentioned along with problematic issues of classifications.
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Introduction
A philosophical background to histological types of 
breast carcinoma
Breast cancers can be and are classified according to many of their as-
pects, with histological presentation being the basis of the World Health 
Organization (WHO) classifications of breast tumors for a long time in 
successive editions of “the blue book” 1-5, further referred to as editions 
in this review.
Mankind has always been interested in making order in the world around 
itself and undertook this with more or less success. The interest in clas-
sifying things, making a difference between the good and the bad, the 
dangerous and the harmless is probably as old as our species. Practical-
ly anything can be classified and everything can be classified along innu-
merable characteristics, features, aspects… etc. A good classification is 
orderly. Order means that everything has a proper place, and can be (vir-
tually) put there as drugs in a pharmacy, where the pharmacist generally 
knows which drawer or shelf to search for to find a given product. Making 
order in biological entities is more difficult. As Bill Bryson mentions in 
his short history of nearly everything, there is great deal of disorder in 
the taxonomy of the animal and plant kingdoms, and compares this to a 
battleground rather than a science or an art 6. Our perception and cata-
loguing of tumors is hopefully closer to the latter similes, but is certainly 
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not perfect. In theory, optimal order in tumor classifi-
cations means that anything one encounters, can be 
(recognizing the human right for mistakes – errare hu-
manum est – , rightly or wrongly) put into a category 
to which it fits; every lesion has its place and can be 
put into only one place in one classification (and other 
places in other classifications). 
The appearance of the 5th edition of the WHO blue 
book on breast tumors 5 made the author think about 
the past and the present of breast cancer classifica-
tion, and initiated this review.
A tumor is a lump, traditionally a palpable lump, in the 
original meaning of the word, a lump of any type. Al-
though all graduates from medical disciplines know 
that “tumor” is, for example, a cardinal symptom of in-
flammation, in the contemporary meaning, tumors are 
often meant to represent neoplastic proliferations on-
ly. However, lumps in the breast (like in other organs) 
can be the results of inflammation (e.g. granuloma-
tous mastitis or posttraumatic fat necrosis), hyperplas-
tic proliferation (like in sclerosing adenosis) or simply 
fluid accumulation (in gross cysts), not only neoplas-
tic proliferations. On the other hand, with the advent 
of breast cancer screening, neoplastic proliferations 
can be present without lump formation. Owing to this 
complexity of clinical and pathological presentation, 
the classification of breast tumors has always faced 
challenges that had been solved according to the ac-
tual global knowledge available on the diseases and 
adherence to traditions, but also according to the 
knowledge and preferences of those who made the 
classification. As such, the 5th edition does not differ 
from earlier ones, it includes benign and malignant 
neoplasms and non-neoplastic disorders (e.g. usu-
al ductal hyperplasia) which may be tumor forming, 
but not all breast lesions that may be tumor forming, 
even not all subsets of neoplastic lesions considered 
as given entities (at one time or the other) by some 
authors.
As every representative of the Homo sapiens species 
is a unique unprecedented and unrepeatable entity, it 
is probable that despite many similarities, all breast 
cancers have minor or major differences. People in-
volved in making classifications can be divided into 
the two broad categories of lumpers and splitters (a 
classification itself), those who want as few categories 
as possible and those who think that minor differenc-
es and similarities in the main group (e.g. breast car-
cinomas) warrant the formation of a new (sub)group. 
Breast cancers themselves may be classified along 
many aspects (size, nodal status, differentiation, prog-
nosis, method of detection, biomarker expression, 
genetic alterations… to mention only a few of the doz-
ens of dozens of possible classifications). The gold 
standard of diagnosing breast cancers is by histology, 
and as the histological appearance of cancers may be 
similar or different, histological typing has been a goal 
since the first WHO classification appearing in 1968 1, 
and despite the insights into the molecular and ge-
netic backgrounds, histology remains the basis of the 
classification today 5.
Histological types of breast cancers are prognostical-
ly relevant 7, and histological type has been included 
as a category I prognostic factor of breast cancers 
by the College of American Pathologists Consensus 
Statement in 1999 8. Even if some types have no sub-
stantial prognostic impact, their recognition may make 
sense for example to allow one to recognize a tumor 
as being primary in the breast. For example, muci-
nous cystadenocarcinomas are extremely rare in the 
breast as primary, and are relatively more common 
in the ovaries or the pancreas, therefore not knowing 
that they may be primary in the breast would immedi-
ately label them as metastatic at this site. A carcinoma 
of the same type and morphology may have dissimilar 
prognosis depending on the site: e.g. adenoid cystic 
carcinoma of the breast has a better prognosis than 
adenoid cystic carcinoma of the salivary glands 5. His-
tological types may be associated with radiological 
findings (e.g. mucinous, encapsulated papillary, “med-
ullary”, some grade 3 invasive (“ductal”) carcinomas 
may mimic benign lesions by being circumscribed; 
lobular carcinomas still have a propensity to remain 
occult… etc.), with different metastatic patterns (that 
of lobular carcinomas differing from the rest), but 
mainly with different morphologies along which they 
have been classified. This review aims to give an over-
view of the five editions of the WHO blue books on 
breast tumors, specifically on breast carcinomas, es-
pecially their types/classes making the frame of their 
classification.
The classifications
As wisely mentioned in the preface of the first edi-
tion, the classifications reflect the then current state 
of knowledge, with modifications almost certain to be 
needed. Indeed, minor and major changes have oc-
curred through the editions. Table I gives basic ideas 
and statistics about the five editions of the WHO blue 
books on breast tumors, whereas Table II summariz-
es the types of malignant epithelial tumors listed in 
the classifications. The speed of the broadening of 
medical knowledge is reflected by the time elapsed 
between the editions (13, 22, 9 and 7 years) and the 
changes in the titles of the volumes starting by his-
tological typing  1,2, continuing as pathology and ge-
HISTOLOGICAL TYPE AND TYPING OF BREAST CARCINOMAS AND THE WHO CLASSIFICATIONS 27
netics 3 and ending with classification 4,5. Each edition 
demonstrates an increase in pages, with an increase 
in page size occurring at the 3rd edition.
The classifications have not followed the same basic 
approach. Starting with a six-tiered categorization of 
benign non-neoplastic proliferations, benign tumors, 
malignant epithelial tumors, malignant mesenchymal 
tumors (sarcomas), mixed malignant tumors (carci-
nosarcomas) and unclassified entities 1, the following 
editions have attempted a histogenetic first delineation 
with biological behavior coming only second 2-5, either 
with benign lesions and in situ carcinomas preceding 
carcinomas 2,5 or starting with invasive epithelial ma-
lignancies 3,4. At one moment (some) papillary tumors 
started to appear under separate cover 3, clinical pres-
entations of breast carcinoma made their way to the 
classification 3, and other minor differences occurred; 
therefore the organization of the classifications is dif-
ferent.
After this brief general summary of the consecutive 
editions, some histological types are put into their his-
torical perspectives. In the following subtitles, I have 
chosen to base the discussion on the 1st edition and 
label many of the discussed entities as they first ap-
peared in the classification and as they appear now. 
Some additional categories missing from the 1st edi-
tion are also discussed, but this is not a comprehen-
sive coverage of all tumors listed. 
1. INTRADUCT AND INTRALOBULAR NON-INFILTRATING 
CARCINOMA (INCLUDING PAGET’S DISEASE OF THE BREAST) 1 - 
IN SITU CARCINOMAS 5
In situ carcinoma refers to an early carcinoma, which 
by definition does not invade and therefore has no 
metastatic potential. It is currently defined by the pres-
ence of a natural barrier, the myoepithelial cell lay-
er around the neoplastic proliferation. The entity im-
plies that normal breast structures (ducts and acini) 
are partially or completely filled with the tumor cells, 
and do not extend further. This is why this entity was 
initially named intraductal, i.e. intraduct non-infiltrat-
ing carcinoma  1. The 2nd edition was the one intro-
ducing the separate entities of ductal carcinoma in 
situ (DCIS) (of solid, comedo, papillary and cribriform 
patterns) and lobular carcinoma in situ (LCIS). The 
papillary DCIS cases illustrated in the text 2 would all 
be micropapillary according to current nomenclature. 
The 3rd edition departed from the architectural classi-
fication (although it states that the architecture should 
be reported), and distinguished between low-grade, 
intermediate grade and high grade DCIS and unusual 
variants (spindle cell, apocrine, neuroendocrine, sig-
net-ring cell, clear cell, squamous) with uncertainty in 
grading; this approach was maintained in the following 
editions 3-5. (The 3rd edition also offered an alternative 
nomenclature for non-invasive ductal neoplasms en-
compassing flat epithelial atypia, atypical ductal hy-
perplasia, and different grades of DCIS in the form of 
ductal intraepithelial neoplasia – DIN). Some forms of 
DCIS recognised by others, (e.g. DCIS with mucin for-
mation 9, cystic hypersecretory DCIS 10) are not part 
of the WHO classifications. 
As mentioned above, LCIS was introduced in the 2nd 
edition, already mentioning lobular neoplasia as an 
alternative name which later became the title of the 
chapter in the 3rd and 4th editions  3,4. The 3rd edition 
also mentions the three-tiered graded lobular intraep-
ithelial neoplasia (LIN) terminology 3, whereas the 4th 
edition, at least in its illustrations returns to the tradi-
tional atypical lobular hyperplasia (ALH), LCIS subdi-
viding terminology and also introduces pleomorphic 
LCIS as a subset  4. This is further expanded by the 
addition of florid LCIS in the 5th edition 5 to the “Non-in-
vasive lobular neoplasia” main chapter divided to ALH 
and LCIS subheadings. In 2017, the American Joint 
Committee on Cancer (AJCC) departed from the tra-
dition of including LCIS in the pTis staging category 
in its Cancer staging manual 11. This was not followed 
by the 8th edition of the Union for International Can-
cer Control (UICC) TNM classification published in 
the same year 12,13, contrarily to what is written about 
this in the 5th edition  5. Thus, followers of the UICC 
classification still continue to stage LCIS as pTis(L-
CIS), which may be supported by the findings that 
screen-detected, biopsy sampled florid and pleomor-
phic LCIS are too often associated with upstaging to 
invasive lobular carcinomas on excision 14.
The UICC TNM classification also includes an in situ 
carcinoma category for Paget’s disease without asso-
ciated DCIS or invasive carcinoma, pTis(Paget) 12. Pa-
get’s disease of the breast was part of the 1st edition 
of the WHO classification and was partly interpreted 
as it is now: infiltration of the epidermis by an “under-
lying intraduct or invasive carcinoma” 1. The difference 
is probably that nowadays the underlying carcinoma 
is more commonly a high grade DCIS involving the 
lactiferous ducts than in earlier times, but an invasive 
carcinoma is quite often associated with this former 5. 
The pTis(Paget) category without these underlying tu-
mors is rare, only 7/114 belonged to this category in a 
series from the European Institute of Oncology 15, the 
percentage reported being 0-13% 5.
2. INFILTRATING CARCINOMA 1 - INVASIVE BREAST CARCINOMA 
OF NO SPECIAL TYPE (IBC-NST) 5
Tumors not fitting into any of the special histological 
variants 1, any of the other categories 2, failing to ex-
hibit sufficient characteristics to achieve classifica-
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tion as a specific histological type  3,4, which cannot 
be classified morphologically as any of the special 
histological types  5 were grouped under an “umbrel-
la” or “waste-basket” category (Tab.  II). This concept 
has therefore been present from the 1st edition, but 
the most proper name for the category needed some 
time to gain acceptance 4,5. Starting as “infiltrating car-
cinoma”, this was preferentially called “invasive duct-
al carcinoma (IDC)” only from the 2nd edition (basi-
cally remaining as such in the 3rd edition, too), with 
a number of synonyms like carcinoma of no special 
type (the currently preferred term occurring as early 
as 1981), infiltrating duct carcinoma not otherwise 
specified (NOS), infiltrating duct carcinoma with pro-
ductive fibrosis, scirrhous carcinoma, infiltrating car-
cinoma, carcinoma simplex  2, and no specific type 
(ductal NST)  3. Approaching the logical aspects, we 
deal with an antagonistic dichotomous categorization: 
there are special types of breast cancer and the rest is 
of no special type (NST) and not “ductal”. Ductal, orig-
inally, was thought to reflect the hypothesized ductal 
origin of these tumors in contrast to the believed lob-
ular origins of lobular carcinomas – none of which are 
considered true now; but as we love traditions, lobu-
lar carcinoma has kept its name, and this is not bad, 
because everyone knows what this term means. To 
better understand the special type versus non-special 
type dichotomization, we could think about the anal-
ogy of colours: the antagonistic category to white is 
not black, but non-white. (It is just a bit ironic that the 
precursor lesion is “ductal” carcinoma in situ.)
Obviously, due to the nature of the definition, this 
group is very heterogeneous in gross and microscop-
ic aspects, and the new histological types of breast 
cancer showing up in consecutive new editions of the 
blue book were all segregated from this one (Tabs. I 
and II). The editors and authors of the 5th edition have 
decided to cut on the number of recognized types and 
to replace some of these (notably oncocytic, lipid-rich, 
glycogen-rich, clear cell and sebaceous carcinoma, 
“medullary carcinoma” and NSTs with neuroendo-
crine differentiation) but not others (like carcinomas 
with apocrine differentiation, mucinous, tubular… etc. 
carcinomas) as special morphological patterns of 
IBC-NST. Pleomorphic carcinoma, carcinoma with 
osteoclast-like giant cells or choriocarcinomatous or 
melanocytic features had been subsets of the NST 
category since the 3rd edition. It is difficult to resist to 
the somewhat humourous basic tripartite grouping 
of breast carcinomas the new edition offers: special 
types – no special types with special morphological 
patterns – and no special types with no (without) spe-
cial patterns (i.e. the rest).
If a component is minor, the tumor must to be catego-
rized according to the predominant pattern, however 
extensive mixtures require multiple diagnoses; this was 
the first mention of multiple recognised morphologies 
within a breast carcinoma 2. Mixed morphologies have 
been recognized for many years, and traditionally they 
meant and were defined as the occurrence of IBC-NST 
admixed with another special type, which was present 
in insufficient quantity (up to 90%) to qualify as a pure 
special type carcinoma. The lower limit of special types 
to qualify as mixed special type (mixed lobular, mixed 
tubular, mixed mucinous, mixed micropapillary were 
the commonest) was 50% 3,4. This left carcinomas with 
less than 50% recognizable special type morphology 
to be classified as NST or IDC NOS, and sometimes 
resulted in surprises when the disease metastasized 
or recurred as a special type carcinoma, suggesting 
another primary tumor. The problem has been dealt 
with most wisely: the 5th edition recommends the use 
of mixed IBC-NST and special type whenever the lat-
ter is present in 10-90% with the estimated proportion 
to be given. For special types being present in <10%, 
the approach is to classify the carcinoma as IBC-NST 
with the option of mentioning the minor special type 
in the description 5. On the other hand, even the new 
edition does not seem to cover the coexistence of two 
special types whether collision tumors or derivates of 
the same parent cells. Tubular and lobular carcinomas 
are known to be associated with lobular neoplasia 
more commonly than a random event 16,17, and there-
fore may be found in association with each other, too. 
Table I. Summary and basic statistics about the WHO Breast blue book editions*.
Edition 1st 2nd 3rd 4th 5th
Year 1968 1981 2003 2012 2019
Authors 14 13 132** 92 153
Countries 12 11 23** 24 21
Pages 37 75 112 240 355
Diseases/entities listed* 29 36 94 113 108
Types of carcinoma recognized* 10 18 40 59 44
*The number of entities and carcinomas listed is subject to subjectivity, as subtypes are sometimes mentioned separately; **The book includes gynaecologi-
cal cancers, too.
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Table II. Entities tabulated in consecutive editions of the blue book on breast tumors*.
1st edition (1968)
Intraduct and intralobular non-infiltrating carcinoma
Infiltrating carcinoma
Special histological variants of carcinoma:
• Medullary carcinoma
• Papillary carcinoma
• Cribriform carcinoma
• Mucous carcinoma
• Lobular carcinoma
• Squamous carcinoma
• Paget’s disease of the breast
• Carcinoma arising in cellular intracanalicular fibroadenoma (i.e. cystosarcoma phylloides)
2nd edition (1981)
Noninvasive
• Intraductal carcinoma
• Lobular carcinoma in situ
Invasive
• Invasive ductal carcinoma
• Invasive carcinoma with predominant intraductal component
• Invasive lobular carcinoma
• Mucinous carcinoma
• Medullary carcinoma
• Papillary carcinoma
• Tubular carcinoma
• Adenoid cystic carcinoma
• Secretory carcinoma (juvenile carcinoma)
• Apocrine carcinoma
• Carcinoma with metaplasia (squamous, spindle-cell, cartilaginous and osseous, mixed type)
• Others (lipid-secreting carcinoma, small cell carcinoma, signet-ring cell carcinoma)
Paget’s disease of the nipple
3rd edition (2003)
Precursor lesions
• Lobular neoplasia
• Intraductal proliferative lesions
• Microinvasive carcinoma
• Intraductal papillary neoplasms
Invasive breast carcinoma
• Invasive ductal carcinoma, NOS
 - Pleomorphic carcinoma
 - Carcinoma with osteoclastic giant cells
 - Carcinoma with choriocarcinomatous features
 - Carcinoma with melanocytic features
• Invasive lobular carcinoma
• Tubular carcinoma
• Invasive cribriform carcinoma
• Medullary carcinoma
• Mucin producing carcinomas (mucinous/colloid carcinoma including cellular and hypocellular subsets, mucinous cystadenocarcinoma, 
columnar cell mucinous carcinoma, signet-ring cell carcinoma) 
• Neuroendocrine tumors
• Invasive papillary carcinoma
• Invasive micropapillary carcinoma
• Apocrine carcinoma
• Metaplastic carcinoma
• Lipid-rich carcinoma
• Secretory carcinoma
u
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Table II. (continued)
• Oncocytic carcinoma
• Adenoid cystic carcinoma
• Acinic cell carcinoma
• Glycogen-rich clear cell carcinoma
• Sebaceous carcinoma
• Inflammatory carcinoma
• Bilateral breast carcinoma
4th edition (2013)
• Precursor lesions
 - Ductal carcinoma in situ
 - Lobular neoplasia (Lobular carcinoma in situ – classic and pleomorphic; atypical lobular hyperplasia)
• Microinvasive carcinoma
• Invasive breast carcinoma
 - Invasive carcinoma of no special type (NST)
 - Pleomorphic carcinoma
 - Carcinoma with osteoclast-like stromal giant cells
 - Carcinoma with melanotic features
 - Invasive lobular carcinoma
 - Classic lobular carcinoma
 - Solid lobular carcinoma
 - Alveolar lobular carcinoma
 - Pleomorphic lobular carcinoma
 - Tubulolobular carcinoma
 - Mixed lobular carcinoma
 - Tubular carcinoma
 - Cribriform carcinoma
 - Mucinous carcinoma
 - Carcinoma with medullary features 
 - Medullary carcinoma
 - Atypical medullary carcinoma 
 - Invasive carcinoma NST with medullary features
 - Carcinoma with apocrine differentiation
 - Carcinoma with signet-ring cell differentiation
 - Invasive micropapillary carcinoma
 - Metaplastic carcinoma NST
 - Low-grade adenosquamous carcinoma
 - Fibromatosis-like metaplastic carcinoma
 - Squamous cell carcinoma
 - Spindle cell carcinoma
 - Metaplastic carcinoma with mesenchymal differentiation (chondroid, osseous, other type)
 - Mixed metaplastic carcinoma
 - Myoepithelial carcinoma
 - Carcinoma with neuroendocrine features
 - Neuroendocrine tumor, well differentiated
 - Neuroedocrine carcinoma, poorly differentiated (small cell carcinoma)
 - Carcinoma with neuroendocrine differentiation
 - Secretory carcinoma
 - Invasive papillary carcinoma
 - Acinic cell carcinoma
 - Mucoepidermoid carcinoma
 - Polymorphous carcinoma
 - Oncocytic carcinoma
 - Lipid-rich carcinoma
 - Gycogen-rich clear cell carcinoma
 - Sebaceous carcinoma
u
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Table II. (continued)
 - …
Epithelial-myoepithelial tumors
 - …
 - Adenomyoepithelioma with carcinoma
 - Adenoid cystic carcinoma
Papillary lesions
 - …
 - Intraductal papilloma with atypical hyperplasia
 - Intraductal papilloma with ductal carcinoma in situ
 - Intraductal papilloma with lobular carcinoma in situ
 - Intraductal papillary carcinoma
 - Encapsulated papillary carcinoma
 - Encapsulated papillary carcinoma with invasion
 - Solid papillary carcinoma (in situ)
 - Solid papillary carcinoma (invasive)
Tumors of the nipple
 - …
 - Paget’s disease of the nipple
Tumors of the male breast
 - …
 - In situ carcinoma
 - Invasive carcinoma
Clinical patterns
 - Inflammatory carcinoma
 - Bilateral breast carcinoma
5th edition (2019)
Non-invasive lobular neoplasia
 - …
 - Lobular carcinoma in situ (classic, florid, pleomorphic)
Ductal carcinoma in situ (DCIS)
 - DCIS of low nuclear grade
 - DCIS of intermediate nuclear grade
 - DCIS of high nuclear grade
 - Invasive breast carcinoma
 - Invasive breast carcinoma of no special type (including medullary pattern, invasive carcinoma with neuroendocrine differentiation, 
carcinoma with osteoclast-like stromal giant cells, pleomorphic pattern, choriocarcinomatous pattern, melanocytic pattern, on-
cocytic pattern, lipid-rich pattern, glycogen-rich clear cell pattern, sebaceous pattern)
 - (Microinvasive carcinoma)
 - Invasive lobular carcinoma
 - Tubular carcinoma
 - Cribriform carcinoma
 - Mucinous carcinoma
 - Mucinous cystadenocarcinoma
 - Invasive micropapillary carcinoma
 - Carcinoma with apocrine differentiation
 - Metaplastic carcinoma (low-grade adenosquamous carcinoma, [high-grade adenosquamous carcinoma], fibromatosis-like meta-
plastic carcinoma, spindle cell carcinoma, squamous cell carcinoma, metaplastic carcinoma with heterologous mesenchymal [e.g. 
chondroid, osseous, rhabdomyoid, neuroglial) differentiation, mixed metaplastic carcinomas)
 - Acinic cell carcinoma
 - Adenoid cystic carcinoma
 - Secretory carcinoma
 - Mucoepidermoid carcinoma
 - Polymorphous adenocarcinoma
 - Tall cell carcinoma with reversed polarity
u
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Although this is not listed in the blue book, by analogy, 
it feels appropriate to call such tumors as mixed tubu-
lar and lobular with the proportion of each given.
Of the patterns listed under IBC-NST, carcinomas 
with neuroendocrine differentiation are the least well 
delineated, and their separation from neuroendo-
crine neoplasias (NEN; forming a separate category 
with neuroendocrine tumors (NETs) of Nottingham 
grade 1 or 2 and neuroendocrine carcinomas (NEC) 
of either small cell or large cell type) is less than ob-
vious. It is clear that neither type B mucinous carci-
noma nor solid papillary carcinoma with neuroendo-
crine differentiation belong to any of these catego-
ries. The ubiquitous small cell carcinomas are rather 
distinctive in terms of light microscopic appearance, 
but no diagnostic boundary has been provided in the 
related chapter to draw the line between small cell 
NEC and large cell NEC 5, and the notion that more 
than two-thirds express neuroendocrine markers 
(chromogranin and synaptophysin) is just disturbing 
as a feature of NECs; how are the less than one-
third negative ones classified as NEC then? The 
rather rare NENs are separated from the IBC-NST 
with neuroendocrine differentiation (which seem to 
be relatively common) by the presence and extent of 
histologic features characteristic of neuroendocrine 
differentiation. “Distinct and uniform enough” neu-
roendocrine features and neuroendocrine marker ex-
pression make a tumor NET or NEC; in the absence 
of these latter or lack of any special histologic type 
defining features, neuroendocrine differentiation will 
remain a pattern of IBC-NST. The segragation is fur-
ther confused by the notion that 10-90% neuroendo-
crine differentiation allows for mixed NENs 5. Finally, 
the fact that breast NENs are described as tumors 
lacking the organoid features of other typical NENs, 
like carcinoid tumors of the lung or NETs of the gas-
trointestinal tract  5, do not make the recognition of 
“distinct and uniform neuroendocrine features” eas-
ier and the distinction between IDC-NST with neu-
roendocrine differentiation and NENs obvious.
3. LOBULAR CARCINOMA 1 - INVASIVE LOBULAR CARCINOMA 
(ILC) 5
This is a special histological type featured in the ini-
tial classification. Interestingly, the example shown in 
the low power figure in the 1st edition does not show 
the features associated with classical ILC. It is more 
a nest forming tumor than one with discohesive cells 
infiltrating in a “lobular pattern”, i.e. single cells, Indi-
an filing, concentric periductal and/or perilobular ar-
rangement. This is because the type was considered 
an indefinite entity at the time, and was interpreted 
as a tumor mainly being intralobular but with super-
imposed invasion of mammary stroma  1. In the 2nd 
edition (and through to the last one), ILC is defined 
as the classical form, on morphological grounds. The 
definition has a reference to the cellular analogy with 
LCIS, a lesion described in 1942 by Foote and Stew-
art  18, but illustrated even earlier as a precancerous 
lesion by Evans 19. The “tubulo-lobular” and solid vari-
ants are also mentioned 2, with the inclusion of further 
variants, the alveolar, the pleomorphic and the mixed 
ones in the 3rd edition 3. All these variants remained 
Table II. (continued)
Neuroendocrine neoplasms
 - Neuroendocrine tumor (Grade 1, Grade 2)
 - Neuroendocrine carcinoma
Papillary neoplasms
 - …
 - Papillary ductal carcinoma in situ
 - Encapsulated papillary carcinoma
 - Solid papillary carcinoma (in situ and invasive)
 - Invasive papillary carcinoma
Epithelial-myoepithelial neoplasms
 - …
 - Malignant adenomyoepithelioma
 - Epithelial-myoepithelial carcinoma
Tumors of the male breast
 - …
 - In situ carcinoma
 - Invasive carcinoma
*The tabulated types of carcinoma appearing at the beginning of the relevant texts are sometimes complemented with variants/subtypes mentioned in the 
main body of the related chapters, and the 5th edition of the book has chapter starting tables in partial contradiction with the main body of the text, and 
therefore the chapter headings and content are better reflected in this table.
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through further editions 4,5. The terminology has slight-
ly and changed disturbingly little without notice with 
“patterns” replacing “variants”; it is not known whether 
this is a conceptual change like with IBC-NST or just 
a stylistic alteration, although the latter is favoured. In 
the last edition, all main headings are presented in 
a structured way, and the ILC chapter states “None” 
under the subheading “Subtype(s)”, what does not 
preclude a reference to “histological subtypes” further 
ahead in the text when alluding to the receptor status 
or the prognosis of different variants/patterns. 
The description of extracellular mucin production as 
a further possible morphologic feature of ILC also oc-
curs for the first time in the 5th edition, although not in 
the ILC chapter, but the general “Introduction to tum-
ors of the breast” and the chapter on mucinous carci-
noma 5. Interestingly, a trabecular variant, which was 
also alluded to by Martinez and Azzopardi in the same 
article as the alveolar  20 never made it to the WHO 
classification, although it is sometimes mentioned in 
current papers 21. It could add a morphologic variant to 
the diagnostic spectrum and would enable non-clas-
sical, non-alveolar, non-solid, non-pleomorphic cases 
to be subclassified among the ILCs with IBC-NST-like 
low-power appearance.
The 3rd edition was the first to mention the loss of 
E-cadherin function behind the typical discohesive 
morphology of ILCs 3. This is further elaborated in the 
later editions, where the loss of other members of the 
E-cadherin complex are also mentioned and a better 
molecular/genetic characterization of ILCs is given 4,5. 
To note, at no point has E-cadherin loss been a defin-
ing criterion of lobular carcinomas in the blue books, 
although it was made clear that this is one of the most 
consistent molecular alteration in this histological type. 
(In contrast, the Armed Forces Institute of Pathology 
fascicles, in their 4th series mention E-cadherin loss 
in the definition of ILCs  22.) It is acknowledged that 
about 15% of ILCs (and lobular neoplasias) may have 
aberrant E-cadherin staining, which may be cyto-
plasmic, weak/focal membranous, and rarely marked 
membranous, but this should not deter the diagnosis 
of a lobular carcinoma whether invasive or in situ, if 
the morphology is in keeping with the diagnosis 5,23,24 
(Fig. 1). On the other hand, non-lobular carcinomas 
may lack E-cadherin expression.
The tubulolobular variant of ILC (tubulolobular car-
cinoma, TLC) was described by Fisher et al. in 1977. 
They found the prognosis of this type of carcino-
ma intermediate between the prognosis of classic 
ILC and tubular carcinoma, and felt that it was a 
philosophical question whether to classify it as a 
variant of tubular or lobular carcinoma. They chose 
the second because they felt that the infiltration pat-
tern was of greater importance than the structures 
seen in the tumor; they also noted that the light mi-
croscopic appearance of tumor cells more closely 
resembled that of classic lobular carcinoma cells 
despite ultrastructural features more suggestive of 
ductal NST carcinoma 25. The statement that about 
one-third of TLCs are associated with lobular neo-
plasia is repeated in the last three editions of the 
blue book 3-5, but lobular neoplasia is not infrequent-
ly associated with tubular carcinomas or low grade 
NST carcinomas either  17. In the 3rd edition, it was 
also stated that E-cadherin studies should clarify 
the classification of TLCs as lobular or tubular. Such 
studies were performed before the publication of 
the 4th edition, and they demonstrated strong mem-
branous staining for E-cadherin (and the catenins if 
tested) in all 17,26,27 or the majority 28 of the overall 76 
TLCs cases tested. Although these results and the 
three-dimensional reconstruction of TLCs  29 favor 
a wrong classification of TLC as lobular carcinoma 
variant, TLC has remained a variant/pattern of ILC 
in the latest edition, too 5. The value of these state-
ments should not be compromised by the phenom-
enon (which is also not described in the blue book) 
that E-cadherin negative “pseudocribriform” and/or 
tubule-like structures (tubules) may rarely occur in 
ILC and their presence should not alter the diagno-
sis of ILC 24,30 (Fig. 2).
About 5% of breast carcinomas have both invasive NST 
carcinoma and ILC features (Fig. 3), a phenomenon 
approached with the category of mixed carcinomas in 
the 3rd and 4th editions of the blue book, but referred to 
as ductulolobular carcinomas in the ILC chapter of 5th 
edition. Of note, the IBC-NST chapter lists mixed IBC-
NST and ILC as an example of mixed carcinoma.
Considering that some ILCs are not of the classic type, 
and IBC-NST-like morphologies exist (solid, trabecu-
lar, alveolar patterns and tubule-like structure forma-
tion may occur), that E-cadherin is not lost in all cases 
of ILC but may be lost in some other forms of IBC, and 
that IBC-NST may have a morphology simulating the 
infiltration pattern of lobular carcinomas (as depicted in 
Figures 2.90 and 9.03 of the 5th edition), the diagnosis 
of ILC is not always easy. Adherence to the morpholog-
ical definition, the use of E-cadherin and/or the caten-
ins (most commonly beta-catenin and p120 catenin) in 
doubtful cases may be a pragmatic approach. Although 
it is widely accepted that membranous E-cadherin and 
alpha-, beta-, gamma- or p120-catenin staining should 
not alter the diagnosis of ILC in a morphologically typ-
ical case, it is advisable to base the diagnosis on im-
munostaining in doubtful cases: making it lobular when 
the staining is lost to altered/aberrant and making it 
non-lobular when it is nicely membranous.
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4. CRIBRIFORM CARCINOMA 1 - INVASIVE CRIBRIFORM 
CARCINOMA (AND TUBULAR CARCINOMA) 5
Although tubular carcinoma is a relatively common 
but special type of breast carcinoma, it was not repre-
sented in the 1st edition. On the other hand, cribriform 
carcinoma was there, but it also included tumors la-
belled as adenoid cystic carcinoma and cylindroma, 
as no experience was available with these rarer types. 
It is to note that the cribriform carcinomas illustrated 
in the book all represent non-high grade cribriform 
DCIS with or without necrosis. Cribriform carcinoma 
has been defined as a type of invasive breast cancer 
in the 3rd edition. The definition of this type included 
the >90% purity rule, but with a “facilitation” to make 
Figure 1. LN with aberrant membranous E-cadherin complex protein expression. Fibroadenoma with lobular neoplasia, 
which can be seen between the 12 and the 3 o’clock position (A: HE x5); with a higher magnification, the discohesive cellular 
composition fulfils the diagnostic criteria of lobular neoplasia (B: HE x70), but the membranous staining with E-cadherin (C, 
x40), b-catenin (D, x40) and p120 (E, x40) are aberrant. S100 highlights the myoepithelial cells (F, x40).
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this diagnosis even if >90% of the tumor was of mixed 
tubular and cribriform patterns with the latter predom-
inating  3,4, but this facilitation was abandoned in the 
5th edition, requiring >90% cribriformity for the diag-
nosis 5. The original description of invasive cribriform 
carcinoma also included a reverse rule, calling tum-
ors with mixed tubular and cribriform patterns with the 
former predominating as tubular carcinomas  31. This 
rule is also part of the Royal College of Pathologists 
current recommendations on reporting of breast can-
cer 10, but the blue book editions never included this 
mention, and required (and still do) >90% tubular car-
cinoma morphology for a pure tubular carcinoma 3-5.
It has also been acknowledged that tubular carci-
nomas have better prognosis than well differentiated 
(grade 1) IBC-NSTs. However, it would be difficult not 
to perceive tubular carcinomas as one extreme end of 
differentiation of IBC-NST, where the better prognosis 
may simply stem from the fact that these tumors are 
required to score 1-1-1 or at most 1-2-1 (3 or 4 overall) 
on the gland/tubule formation, nuclear pleomorphism, 
adjusted mitotic rate scheme used for grading. (Highly 
atypical nuclei exclude the diagnosis, and low prolifer-
ation is a “non-defining” characteristic of tubular car-
cinomas and the luminal A category they belong to 5). 
In contrast, grade I IBC-NSTs may score anything to 
make a grading sum of up to 5, and even their score 1 
for gland/tubule formation needs only >75% glandular 
differentiation and not >90%. Therefore, tubular car-
cinomas are probably best viewed as the best differ-
entiated carcinomas of the best differentiated (grade 
I) IBC-NSTs; nevertheless, they are worth being sep-
arated from the rest, due to their excellent prognosis 
and the possibility to omit adjuvant systemic and axil-
lary treatment in most of them 5.
5. MUCOUS CARCINOMA 1 - MUCINOUS CARCINOMA 5
Termed mucous carcinoma in the first edition  1 and 
preferentially mucinous in the subsequent ones  2-5, 
this type was characterised from the onset by sub-
stantial extracellular mucin formation. In the 3rd edi-
tion, this histological type became a part of a larg-
er group of breast cancers characterized by mucin 
formation in general. The larger group also included 
tumors with intracellular mucin production like muci-
nous cystadenocarcinoma, its non cystic/solid variant, 
i.e. columnar cell mucinous carcinoma (featuring only 
in this edition with 2 cases previously reported) and 
signet-ring cell carcinoma, but did not include others 
like solid papillary carcinoma with extracellular mucin 
formation or mucoepidermoid carcinoma  3. This was 
also the first classification to mention a hypocellular 
(type A by Capella et al.) and a cellular variant (type 
B by Capella et al.) of mucinous carcinoma, which re-
mained in the subsequent editions  4,5, but no refer-
ence was made to indeterminate or transitional types 
labelled AB by Capella et al., which made up one fifth 
of their initial series 32. Indeed, it is sometimes difficult 
to classify mucinous carcinoma into type A or B, but 
this matter does not seem to be of great importance, 
as this subclassification has no clinical relevance at 
present. As mentioned earlier, mucin forming DCIS 
has not received attention in the WHO classification of 
mucin forming carcinomas.
Two new subsets of IBC are discussed in the muci-
nous carcinoma chapter of the 5th edition. 
One is the subset of carcinomas with both focal extra-
cellular mucin formation and discohesive cells lacking 
E-cadherin expression, often showing an association 
with lobular neoplasia. These tumors are generally 
(but not unanimously) 33 presented as ILC with extra-
cellular mucin production in the literature 9,30, but are 
not mentioned under the invasive lobular carcinoma 
heading.
The second is a subset mentioned under both the Mu-
cinous carcinoma and the Invasive micropapillary car-
cinoma chapters, and is characterized by extracellular 
mucin and an inside-out reversed polarity of its cells, 
i.e. a micropapillary pattern. Probably first described as 
an entity in 2002 34, mucinous carcinoma with micro-
papillary features (invasive micropapillary mucinous 
or mucinous micropapillary carcinoma) has been as-
sociated with a worse prognosis than pure (non-mi-
cropapillary) mucinous carcinoma  5. The extent mi-
cropapillary architecture needs to be present for this 
Figure 2. Tubules in ILC. This is an ILC with some trabecu-
lar pattern (alveolar elsewhere) which demonstrates some 
tubules (arrow and inset; b-catenin, x5 and x20 - inset). All 
tumor cells are b-catenin negative (and were also E-cadherin 
negative and –  high molecular weight cytokeratin/34bE12 
positive – not shown.) Whether these tubules are genuine 
ILC components or minor non-ILC component lacking the 
function of the E-cadherin-complex is subject to interpreta-
tion, but the former is favoured.
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Figure 3. Mixed IBC-NST and lobular carcinoma or ductulolobular carcinoma? The illustrated tumor was diagnosed on 
core needle biopsy as IBC-NST (A, HE, x40) and had a HER2-positive (+) (B, HER2, x400), ER-negative (-), PR- phenotype 
(not shown). After primary systemic treatment with a taxan containing regimen and trastuzumab. Following this neoadjuvant 
therapy the tumor bed was suggestive of pathological complete regression (C, HE x100), except for about a 10% area where 
ILC was identified (D, HE x400) with the typical E-cadherin- (not shown), b-catenin- (E, b-catenin x400), ER+ (F, ER x400), 
PR+, HER2- phenotype, proving a well defined mixed tumor of different histological types and biomarker expression.
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entity in order to qualify as such is not described in the 
WHO classification, >50% was used in some series 35-
36. Even the diagnostic criteria for reliably diagnosing 
this entity are less than perfectly described. The pres-
ence of reverted (“inside-out”) pattern demonstrated 
by epithelial membrane antigen (MUC1) immunohis-
tochemistry might not be sufficient, as this feature is 
seen in large numbers of pure mucinous carcinomas 
and fails to discriminate between the two entities 35-37. 
It is therefore likely that series of pure mucinous carci-
nomas reported previously harbour a number of cases 
that would be diagnosed as micropapillary variants by 
Liu et al, and the good overall prognosis of mucinous 
carcinomas was derived from such aggregated series. 
However, when micropapillary mucinous cases are 
separated from the pure mucinous ones, they show a 
prognosis worse than that of pure mucinous carcino-
mas without a micropapillary pattern and better than 
that of invasive micropapillary carcinomas 36.
6. MEDULLARY CARCINOMA 1 - IBC-NST WITH MEDULLARY 
PATTERN 5; THE RISE AND FALL OF A TYPE WITH FAVOURABLE 
OUTCOME
This entity was already present in the 1st edition of 
the classification  1. In general, pathology medullary 
carcinoma reflected a carcinoma with dominant tu-
mor parenchyma in contrast to scirrhous carcinoma 
where the stroma and desmoplasia predominated 
over parenchyma, the first being soft, the other hard 
on palpation. In breast pathology, medullary carcino-
ma partially reflected this aspect, but also syncytial 
arrangement of the tumor cells. In the 1st edition, the 
exaggerated lymphoid stroma was not a necessary 
prescription for this histological type, and there was 
a notion that the tumor could be of good prognosis 
even in the absence of a lymphoid stroma. This is 
in contrast with the analysis of Ridolfi et al, where 
the lymphoid infiltrate was found to be of prognostic 
value: medullary carcinomas with pronounced mono-
nuclear infiltrate had 91% 10-year-survival in opposi-
tion to 71% for the cases with fewer mononuclears 38. 
The prominent lymphocytic stroma became a defin-
ing feature in the 2nd edition and remained as such in 
the 3rd 2,3, which was the first to give further stringent 
criteria for this special type: at least 75% syncytial 
architecture; lack of glandular structures; cells with 
abundant cytoplasm, vesicular, generally rounded 
nuclei with marked (or at least moderate) pleomor-
phism; circumscription. The classification was incon-
clusive with regards to DCIS component, stating it as 
a possible exclusion criterion  3. Atypical medullary 
carcinomas were defined for the first time in this edi-
tion of the blue book as having the syncytial architec-
ture and 2 or 3 of the other type defining criteria on 
lymphoid stroma, circumscription, nuclear morpholo-
gy and lack of glandular structures. Infiltrating duct-
al carcinoma with medullary features also made its 
way to the classification in the 3rd edition, to replace 
atypical medullary carcinoma, and keep the medul-
lary carcinoma type as clear as possible, and avoid 
confusion with it. With the 4th edition, medullary car-
cinoma vanished from the chapter headings and was 
lumped together with atypical medullary carcinoma 
and invasive carcinoma NST with medullary features 
under the heading of carcinomas with medullary fea-
tures  4. This change in policy was partly due to the 
suboptimal reproducibility of medullary carcinoma as 
a special type, and the fact that tumors with some but 
not all features of medullary carcinoma shared many 
aspects (like association with BRCA1 germline muta-
tion or a common triple-negative phenotype) with it. 
Unfortunately, there remained three different ICD-O 
codes for the entities listed, and therefore many sta-
tistics based on these codes did not account for the 
change in policy towards the diagnosis of medullary 
carcinoma 4. Finally, the 5th edition eliminated medul-
lary carcinoma as a distinct histological type of breast 
carcinoma, and made it a distinct pattern of IBC-NST 
that is characterized by predominance of stromal tu-
mor infiltrating lymphocytes (sTILs) and high grade 5. 
This is in line with the early observation by Ridolfi 
et al, and contemporary reports and meta-analyses 
that large numbers of sTIL are of prognostic impor-
tance  39,40, and may explain the better prognosis of 
not only the former pure medullary carcinoma group, 
but also other high grade carcinomas with a lympho-
cyte predominant morphology.
7. SQUAMOUS CARCINOMA 1 - METAPLASTIC CARCINOMA 5
Of the full range of metaplastic carcinomas, only 
squamous carcinoma was recognized as a separate 
entity in the 1968 classification  1, to stepwise get to 
all the types recognized by the 5th edition (Tab.  II). 
The >90% purity rule is not mentioned in the related 
chapter. A mixed metaplastic carcinoma category is 
also defined with either different metaplastic compo-
nents being present or the admixture of metaplastic 
and non-metaplastic adenocarciomatous compo-
nents, where the percentage of each component re-
quires reporting. According to the description with no 
percentage requirement, it seems that any amount of 
metaplasia qualifies a breast carcinoma as metaplas-
tic. However, the last sentence of the histopathology 
section on metaplastic carcinoma states that IBC-
NSTs may have a very tiny metaplastic component, 
which should be noted in the report, and this is proba-
bly best interpreted as an allusion to what is described 
under mixed carcinomas: if <10% is of special type, 
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this should be noted, but the carcinoma is classified 
as IBC-NST  5. This might be in agreement with the 
statement (made under a different WHO classification 
in effect) that basal-like grade III invasive ductal (NST) 
carcinomas often demonstrate squamous metapla-
sia 41; should they now be (mixed) metaplastic carci-
nomas if this feature exceeds 10%? – according to the 
rule, they should.
When one speaks about metaplasia in the breast, the 
most obvious term that comes to mind is apocrine 
metaplasia. Nevertheless, apocrine carcinoma or car-
cinomas with apocrine features have never been part 
of the metaplastic carcinoma group. As they were not 
even represented in the 1st edition, they are discussed 
separately, after the entities appearing in the 1968 edi-
tion.
8. PAPILLARY CARCINOMA 1 - CARCINOMAS WITH A PAPILLARY 
MORPHOLOGY
The papillary pattern is easy to discern, and sever-
al organs (like the thyroid gland, kidneys, ovaries… 
etc.) have papillary carcinomas. (Benign and border-
line papillary tumors are also well recognized, and 
the gastrointestinal tract features villous tumors with 
similar architectural patterns). The papillary carcino-
ma structure requires fibrovascular cores covered by 
neoplastic cells, in contrast to “micropapillae” which is 
a misnomer and does not refer to small papillae, but to 
epithelial outgrowths without fibrovascular cores. The 
breast has a number of papillary carcinomas, and the 
use of papillary carcinoma without further qualifiers is 
improper. These tumors are also classified as part of 
mammary papillary lesions, which can be hyperplas-
tic, neoplastic and in the latter category benign, in situ 
and invasive. 
The 1st edition of the blue book mentions intracystic 
and intraductal papillary carcinomas with a prolifera-
tion similar to intraductal papilloma but with cellular 
atypia and features of malignancy as well as infiltra-
tion of the stroma at the base of the papillary growth. 
The illustrations appear more micropapillary (epithe-
lial cell outgrowths without fibrovascular cores) than 
papillary 1. The second edition stressed the papillary 
structures of the invasive component  2, and a carci-
noma with papillary lymph node metastasis is also 
illustrated. Tumors with >90% papillary invasive com-
ponent are admittedly extremely rare 3-5, and although 
invasive papillary carcinoma has been part of the clas-
sification since the beginning (with the described al-
teration in what was meant by the term), other special 
forms of papillary carcinomas are more common. In 
the 5th edition, papillary DCIS stands alone (separat-
ed from the DCIS category where it is also mentioned 
as a pattern of growth), and together with encapsulat-
ed papillary carcinoma, solid papillary carcinoma (in 
situ and invasive) and invasive papillary carcinoma, it 
forms the group of carcinomas listed under papillary 
neoplasms. 
However, other carcinomas like the mucinous cysta-
denocarcinoma and the tall cell carcinoma with re-
versed polarity may have papillary areas. The latter 
is a new entity in the classification, first described 
under the lengthy name of breast tumor resembling 
the tall cell variant of papillary thyroid carcinoma  42, 
and also mentioned as a variant of solid papillary 
carcinoma  43, with relatively few cases and several 
alternative names in the literature. Although many of 
these names had reference to the common papillary 
architecture of the tumor, the final name adopted by 
the WHO classification has omitted this. To many, re-
versed polarity in breast pathology is associated with 
the image of the first morphology described as such, 
and this is the inside-out pattern of invasive micropap-
illary carcinoma, where the reversal of polarity seems 
complete, according to our current understanding of 
this structural phenomenon 44. Despite the search for 
a good name, reversed polarity in tall cell carcinoma 
with reversed polarity does not always adequately 
describe the phenomenon of the nuclei being placed 
towards the centre or apical pole of the cells from the 
common basal location. Reversed polarity (like in in-
side-out or upside-down) would suggest that all nuclei 
are at the top of the cells (and this is often the case, 
but not always; nuclei may be more central in loca-
tion), and therefore altered polarity might have been 
more descriptive.
In contrast to the rarity of invasive papillary carcino-
ma, invasive micropapillary carcinomas (described 
in a number of other organs too), not demonstrating 
fibrovascular coreless epithelial outgrowths (like in 
DCIS), but rather showing an inside-out reverted po-
larity pattern with a typical cuticule-like microvillous 
secretory surface towards the stroma and therefore a 
gap between the stroma and the neoplastic epithelial 
cells, is not uncommon, especially in its mixed form. 
It has made its first inclusion into the classifications 
in the 3rd edition and has remained thereafter without 
great alterations 3-5
9. APOCRINE CARCINOMAS 1 - CARCINOMAS WITH APOCRINE 
DIFFERENTIATION 5
As carcinomas with predominant cells having abun-
dant eosinophilic cytoplasm are reminiscent of apo-
crine metaplasia, they made their way to the classifi-
cation in the 2nd edition 2. Carcinomas with cytological-
ly and immunohistochemically apocrine cells in >90% 
of the tumors were classified as apocrine in the 3rd edi-
tion 3; according to the description the immunoprofile 
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is typically GCDFP15 positive (+), bcl2 negative (-), 
usually estrogen receptor (ER)- and progesterone re-
ceptor (PR)- and often androgen receptor (AR)+.  The 
4th and 5th editions discuss these tumors under the 
heading of “Carcinomas with apocrine differentiation”, 
recognizing that several histological types may show 
apocrine morphology and immunophenotype: those 
listed beside IBC-NST include invasive micropapil-
lary, lobular and mucinous carcinomas. Furthermore, 
encapsulated papillary carcinoma of apocrine differ-
entiation has also been reported 45,46. The 5th edition 
defines apocrine differentiation by light microscopic 
morphology as cells with distinct cell borders, abun-
dant granular eosinophilic or vacuolated cytoplasm, 
large round to oval nuclei and prominent nucleoli and 
a GCDFP-15+, ER- PR- AR+ immunophenotype  5. 
Nothing is said about the classification of tumors 
having light microscopic apocrine features with some 
deviation from the described immunophenotype. The 
earlier wording  3,4 allowed these to be classified as 
apocrine.
10. OTHER SPECIAL TYPES
A number of other types or clinical presentations (e.g. 
inflammatory breast carcinoma or male breast can-
cer) not specifically listed in the previous paragraphs 
are represented in the classifications and Table II. 
The examples detailed above serve as illustration to 
changes, rules of classification, and/or represent the 
most frequent types of breast cancers encountered.
Although we as pathologists are much concerned 
about an as precise as possible classification of breast 
tumors, our clinical colleagues are more pragmatic in 
their approaches, generally distinguishing between 
ductal, lobular, sometimes a mixed ductal and lobular, 
and other types as examplified by the reports of some 
of their clinical trials 47,48.
Concluding remarks about histological 
typing
There has clearly been a development in understand-
ing breast carcinoma, its development, morphology 
and molecular/genetic backgrounds. For example, the 
early belief that usual type ductal hyperplasia (UDH) 
precedes atypical hyperplasia (ADH) which then pro-
gresses to DCIS and invasive carcinoma has been 
refuted, and UDH is now considered a hyperplastic 
proliferation, whereas ADH is a neoplastic one. Start-
ing from 10 types of noninvasive and invasive carci-
nomas, of which one (carcinoma arising in cellular 
intracanalicular fibroadenoma) has practically disap-
peared, some half a hundred distinct or overlapping or 
encompassing entities are recognized now and form 
the basis of the classification which – as it is often the 
case – achieves goals but fails to make an idealis-
tic absolute order. The WHO blue books have always 
been written by some of the most prominent experts 
in the field, and having been part of the process was 
a rewarding experience to be remembered. The pres-
ent edition, 51 years after the first one, is probably the 
best that could be achieved at this point, but there is 
still ground for improvement.
Theoretically, a classification should allow all cases to 
be allocated to one class or the other, but in practice 
there always seem to be cases that defeat the artificial 
categories created. Therefore, it seems that there is 
no proper classification without an “others” category, 
which in the case of invasive breast carcinomas is the 
IBC-NST without distinct patterns.
Optimally, a tumor should be only classified (and cod-
ed) as belonging to one class, and this would require 
easily reproducible and obvious categories defined on 
the basis of unique features. “It is unknown whether 
these tumors represent a subtype of ILC or mucinous 
carcinoma” – write the authors of the chapter on mu-
cinous carcinoma when they deal with the lobular car-
cinomas that form extracellular mucin 5, and they are 
right, as these tumors fit both the definitions of lobular 
carcinomas (defined principally by their discohesive 
cells) and of mucinous carcinomas (defined principal-
ly by the presence of extracellular mucin). The same 
overlaps are acknowledged or may arise in carcino-
mas with apocrine differentiation, a micropapillary and 
a mucinous look, a papillary architecture and a meta-
plastic trait… etc. A person can be of short stature and 
obese together and the presence or color of his/her 
hair will depend on neither of these features. There-
fore, a classification that includes e.g. overweight/
obese – deviating from normal height – bold as cat-
egories, will allow several proper classifications, but 
none of which would be “the ideal”. 
If we are to have obvious categories for classification, 
we should have obvious none overlapping features to 
allow us to properly allocate tumors into categories 
and further similar organizing principles to subdivide 
the larger categories into subcategories, like the king-
doms, phyla, classes, orders, families, genera in tax-
onomy. Even the biologic behaviour of tumors is diffi-
cult to segregate into categories: it would seem obvi-
ous to have benign (white) and malignant (black) as 
two major categories (as done by the 1st edition of the 
WHO classification), but there are so many shades 
of gray in between (carcinomas of better and worse 
outcome) and even some entities with unknown be-
haviour, that even such an organization would not be 
as obvious as initially believed. Lumping as many as 
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possible into two categories at one extreme or split-
ting each tumor into an individual place in the system 
– something that personalized treatment would per-
haps wish to achieve – are not what a usable classifi-
cation at human scales can do, especially if it wishes 
to be congruent with traditions. 
We now have a system with diagnostic categories of 
carcinomas that are still based on morphologies with 
possible overlaps (histological types)  5. Some enti-
ties share the name of previously differently defined 
diseases (e.g. mixed carcinomas, cribriform carcino-
ma) and alert to caution when reading papers from 
the past, using alternative definitions. Some entities 
that have been described by others (e.g. tubulopap-
illary carcinoma  49 in addition to those already men-
tioned) are not recognized by the WHO classification 
as separate entities, and are therefore not part of the 
system, just as IBC-NSTs (the “Others” category). We 
also have treatment influencing stratifications on the 
basis of e.g. histological grade or biomarker expres-
sion (ER, PR, human epidermal growth factor recep-
tor 2 – HER2, stromal tumor infiltrating lymphocytes – 
sTILs, targetable driver mutations, gene expression 
profiles… etc.), and this seems to be the way our clin-
ical colleagues would like to simplify their approaches 
to breast cancer, where histological typing is simply 
missing from the results of some recent milestone 
clinical trials 50,51. However, as stated in the introduc-
tion, histological types matter, have clinico-patholog-
ical correlations worth knowing for optimal manage-
ment and add to the art of pathology.
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